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Gluteal muscle contracture (GMC) is a chronic fibrotic disease of gluteal muscles due to 
multiple  etiologies.  The  main  pathologic  process  is  characterized  by  proliferation  of 
fibroblasts and excessive accumulation of collagen in the extracellular matrix of the muscle. 
Sphingosine-1-phosphate  (S1P)  is  a  bioactive  sphingolipid  and  has  been  reported  to  be 
associated with various fibrotic diseases. However, the role of S1P in GMC remains unknown. 
Here  in  this  article,  High-performance  liquid  chromatograghy  and  immunohistochemistry 
were applied to evaluate S1P localization and expression in clinical samples from patients 
with GMC, Quantitative real time PCR, Western blot, and enzyme-linked immunosorbent 
assay  were  used  to  explore  the  link  between  transforming  growth  factor-β1  (TGF-β1), 
plasminogen activator inhibitor-1(PAI-1) and S1P. The results showed that S1P was enhanced 
in contraction band (CB) tissues. Studies using the cell proliferation and transformation assay 
indicated  that  exogenous  S1P  stimulated  CB  fibroblast  proliferation  in  a  time-dependent 
manner  and  in  higher  concentration  also  in  a  dose-dependent  manner.  Furthermore,  we 
demonstrated that S1P not only promoted collagen type I production, but also up-regulated 
mRNA and protein expression of transforming growth factor-β1 and plasminogen activator 
inhibitor-1. These findings suggest that S1P may regulate increased synthesis of collagen and 
other  fibrogenic  factors,  and  significantly  contributes  to  the  process  of  gluteal  muscle 
scarring in patients with GMC. 
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Gluteal  muscle  contracture  (GMC)  is  a  chronic  fibrotic  disease  of  gluteal  muscles 
resulting from multiple etiologies (Valderrama 1970; Zhao et al. 2009). GMC is characterized 
by proliferation of fibroblasts and excessive accumulation of collagen in the extracellular 
matrix (ECM) of muscles (Zhao et al. 2010). During the process, sphingosine-1-phosphate 
(S1P),  which  is  generated  during  sphingomyelin  metabolism  as  a  pleiotropic 
lysophospholipid mediator (Donati et al. 2007; Alvarez et al. 2007), stimulates fibroblast 
proliferation. Under normal physiological conditions, the concentration of S1P in cells is low 
and is tightly regulated by the equilibrium between its formation (catalysis by SphK) and 
degradation (catalyzed by S1P lyase and S1P phosphatase) (Maceyka et al. 2005). S1P is 
known to be one of the most common fibrotic mediators and has a close relationship with 
many other fibrotic factors, including transforming growth factor (TGF)-β, connective tissue 
growth  factor  (CTGF),  and  platelet-derived  growth  factor  (PDGF),  at  the  receptor  and 
post-receptor levels (Sauer et al. 2004; Gordon and Blobe 2008). 
TGF-βs  are  important  members  of  the  TGF  superfamily  and  play  key  roles  in  cell 
growth,  differentiation,  migration,  ECM  production,  and  development  (Verrecchia  and 
Mauviel 2007). Numerous studies have demonstrated that TGF-β1 is expressed at high levels 
during tissue remodeling, and affects the formation of connective tissue by stimulating the 
transcription of genes encoding ECM proteins (Liu et al. 2006). Recently, several reports 
have  suggested  that  TGF-β1’s  profibrotic  effects  may  be  partially  mediated  by  the  S1P 
pathway (Kono et al. 2007). Plasminogen activator inhibitor-1 (PAI-1), a member of the serpin superfamily of serine 
protease  inhibitors,  is  capable  of  directly  degrading  matrix  components  and  indirectly 
inhibiting the deposition of ECM by activating latent matrix metalloproteinases (MMPs). 
PAI-1  is  the  major  physiologic  inhibitor  of  the  plasminogen  activator/plasmin  protease 
system
 and can lead to fibrosis in various organs (Cate and Lawrence 2007). In addition, 
PAI-1 can be regulated by the S1P pathway (Paugh et al. 2008). Although a fibrogenic role 
has been documented for S1P during fibrosis in various tissues and organs, the role in muscle 
fibrosis is not yet known. This study was designed to study the role of S1P in muscle fibrosis 
in patients with GMC. 
 
Materials and Methods 
 
Tissue specimens 
Tissue samples (23 contraction bands (CB) and 23 adjacent normal muscle samples) 
were  collected  from  patients  with  GMC  between  January  2007  and  March  2008  at  the 
Urumqi General Hospital of Lanzhou Military Region and the Second Affiliated Hospital of 
Medical College. All procedures involving sample collection were approved by the ethical 
board of the Urumqi General Hospital of Lanzhou Military Region and the Second Affiliated 
Hospital of Medical College, and followed the Declaration of Helsinki Guidelines. Informed 
consent was obtained from all of the involved patients. All 23 patients (10 males and 13 
females;  age  range:  7~27  years)  were  operated  with  CB  releasing  surgery,  as  described 
previously (Zhao et al. 2009).    
Cell isolation and culture 
CB fibroblasts isolated from CB tissues of GMC patients were used for in vitro cell 
culture study. Tissue specimens were cut into blocks of approximately 2× 2 mm
2, then washed 
with distilled water and placed into tissue culture dishes containing DMEM media with fetal 
calf serum, gentamicin, and amphotericin B (Invitrogen, Carlsbad, CA, USA) for incubation 
at  overnight.  Thereafter,  DMEM  media  was  changed  three  times  a  week.  The  isolated 
fibroblasts  were  subcultured  with  0.1%  trypsin  and  0.02%  EDTA  in  Ca
+-free  minimum 
essential medium (MEM) at 80–90% confluence. Only cells past 3-5 generations were used 
for the further analysis. 
 
Quantitative real-time reverse transcription-PCR (qRT-PCR) 
Total  RNA  was  extracted  from  fibroblasts  using  TRIzol  reagent  (Invitrogen). 
First-strand cDNAs were synthesized by using the RevertAid First Strand cDNA Synthesis 
Kit (Fermentas, Vilnius, Lithuania) according to the manufacturer’s instructions. To quantify 
mRNA  expression  of  TGF-β1  and  PAI-1,  qRT-PCR  using  SYBR
®  Premix  Ex  Taq
TM  II 
(TaKaRa, Dalian, China) was performed. The gene for β-actin was amplified as the internal 
control.  Sense  and  antisense  gene-specific  primers  used  in  the  PCR  were:  TGF-β1, 
5'-CGAGAAGCGGTACCTGAAC-3'  and  5'-TGAGGTATCGCCAGGAATTGT-3';  PAI-1, 
5'-CGGCTGGTGCTGGTGAATG-3'  and  5'-CATCGGGCGTGGTGAACTC-3';  β-actin, 
5'-ATCGTGCGTGACATTAAGGAGAAG-3'  and  5'-CATCGGGCGTGGTGAACTC-3'. 
Real-time  measurements  of  gene  expression  were  performed  with  the  iQ5
TM  Multicolor Real-Time  PCR  and  Detection  System  (Bio-Rad,  Hercules,  CA,  USA).  Relative  mRNA 
levels were calculated by the 2
-ΔΔCT method. Quantitative real-time PCR experiments were 
repeated in triplicate. 
 
Immunohistochemistry 
Immunohistochemistry  was  performed  on  paraffin  sections,  as  described  previously 
(Zhao  et  al.  2010).  Briefly,  paraffin  sections  were  deparaffinized,  then  soaked  in  0.3% 
hydrogen  peroxide  in  methanol  to  inactivate  endogenous  peroxidase  activity.  After  mild 
treatment with 0.05% trypsin-EDTA, the sections were incubated with 10% goat serum to 
block  non-specific  protein  binding.  The  blocked  sections  were  incubated  with  antibodies 
against S1P (1:600; Lpath, San Diego, CA, USA), or antibodies against TGF-β1 and PAI-1 
(both  1:300;  Santa  Cruz  Biotechnology,  Santa  Cruz,  CA,  USA)  at  4° C  overnight.  After 
incubation with the primary antibodies, the sections were incubated with secondary antibody 
and  alkaline  phosphatase  streptavidin  (Vector  Laboratories,  Burlingame,  CA,  USA).  The 
sections were then stained using the Vector Red Alkaline Phosphatase Substrate Kit (Vector 
Laboratories), according to the manufacturer’s instructions, and counterstained with Mayer’s 
hematoxylin. One section from each series was incubated with phosphate buffered saline 
(PBS) in lieu of the first antibody for use as a negative control. The staining intensities were 
graded semi-quantitatively using the following scale: (-), no staining; (+), weak staining; (++), 
moderate staining; and (+++), strong staining. 
 
Western blotting Crude proteins were extracted from S1P–treated fibroblasts, and protein concentrations 
were  quantified  using  the  BCA  Protein  Assay  (Pierce,  Rockford,  IL,  USA).  Equivalent 
amounts of proteins (20 μg) were fractionized by SDS-PAGE and subsequently transferred to 
polyvinylidene difuoride (PVDF) membranes (Bio-Rad). The membranes were then blocked 
with  10%  fat-free  skim  milk  powder  in  PBS  containing  0.1%  Tween  20  (PBST),  and 
incubated with antibodies against TGF-β1 or PAI-1 (both 1:200). After a series of brief PBST 
washes,  the  membranes  were  incubated  with  the  appropriate  species-specific  horseradish 
peroxidase-conjugated antibodies (1:5000; Jackson ImmunoResearch, West Grove, PA, USA). 
Antibody-specific bands were visualized using standard ECL chemiluminescence reagents 
(Pierce) and photographed. The density of each band was measured by densitometry. The 
relative expression of ʱ-SMA, TGF-β1 and PAI-1 proteins were normalized to the expression 
of the internal control (β-actin). 
 
High-performance liquid chromatography (HPLC) analysis 
Extraction of S1P from tissues was carried out as described previously (Min et al. 2002). 
Briefly, tissue samples were homogenized and ultrasonicated in ice-cold water. Methanol was 
added and the samples were ultrasonicated for an additional 10 min in ice-cold water. Lipids 
were extracted by adding 500 μl of CHCl3/1 M NaCl (1:1 v/v) and 25 μl of 3 M NaOH. The 
basic  aqueous  phase  was  transferred  to  a  siliconized  glass  tube  and  all  of  the  aqueous 
fractions were combined. The aqueous phase containing S1P was mixed with 150 μl of buffer 
and  50  units  of  alkaline  phosphatase  (Sigma,  St.  Louis,  MO,  USA).  The  mixture  was 
incubated at 37C for 45 min and terminated by addition of HCl. The pooled CHCl3 phase was washed three times with alkaline water and then dried under nitrogen in siliconized glass 
tubes. The dried lipid residue was resuspended in 200 μl of ethanol for 30 min. The dissolved 
lipid solution was incubated for 1 h at room temperature. Sample analysis was carried out 
with  an  Agilent  1100  HPLC  instrument  (Santa  Clara,  CA,  USA).  The  derivatives  were 
detected  using  a  spectrofluorometer,  with  an  excitation  wavelength  of  340  nm  and  an 
emission wavelength of 455 nm. 
 
Cell proliferation 
CB fibroblast cells were plated on 96-well plates at a density of 5× 10
3 cells/well. Plated 
cells  were  synchronized  overnight  in  serum-free  media  and  then  treated  with  varying 
concentrations  of  S1P  for  24,  48  or  72  h.  Cell  proliferation  was  examined  using  a  cell 
proliferation assay kit (Invitrogen), according to the manufacturer’s instructions. Absorbance 
was  measured  at  OD450  and  data  were  expressed  as  the  fold-change  relative  to  control. 
Absorbance measurements were performed independently three times. 
 
Measurement  of  procollagen  type  I  C-peptide  with  enzyme-linked  immunosorbent  assay 
(ELISA) 
Procollagen type I C-peptide (PICP) concentrations were determined by ELISA. Briefly, 
fibroblasts were plated overnight in culture media at a density of 1× 10
5 cells/well on 12-well 
dishes. Plated cells were synchronized overnight in serum-free media and then treated with 
varying  concentrations  of  S1P.  After  media  isolation,  collagen  type  I  production  was 
measured using a PICP ELISA kit (TaKaRa), according to the manufacturer’s instructions. The expression of PICP was normalized for the amount of cellular protein in each well. 
 
Statistical analysis 
All values were expressed as the mean ±  SEM. The paired T-test and one-way ANOVA 
test were used to examine differences between groups. All statistical analyses was performed 
using SPSS 13.0 software. P-values <0.05 were considered significant. 
 
Results 
 
S1P level is increased in contraction band tissues 
Initially, we performed immunohistochemistry to determine the localization and level of 
S1P in CB and adjacent muscles. The results showed that CB fibroblasts contained prominent 
pools  of  S1P.  The  S1P  level  was  remarkably  high  in  fibroblasts  (+++;  arrowhead)  and 
vascular endothelial cells (+++; arrow) in contraction bands (Fig. 1A). In contrast, S1P was 
weakly and sparsely detected in vascular endothelial cells in adjacent muscle sections (+; Fig. 
1B). This pattern of S1P level was further confirmed by HPLC analysis, which showed that 
S1P was significantly enriched in contraction bands, as compared to that in adjacent normal 
muscle (Fig. 1E).   
 
S1P stimulates proliferation of CB fibroblasts 
The high level of S1P in CB of fibrotic muscle suggests its pathophysiological role in 
fibroblast. To address this, CB fibroblasts were treated with various concentrations of S1P for 24, 48 or 72 h to investigate the effect of S1P on proliferation of CB fibroblasts. As shown in 
Figure 2, upon S1P treatment, CB fibroblasts exhibited a time-dependent increase in basal 
cell  proliferation  (0  μM  S1P)  and  a  time-dependent  progressive  increase  at  all  different 
treatment  levels.  In  addition,  CB  fibroblasts  showed  a  dose-dependent  increase  in 
S1P-mediated cell proliferation at all time points examined (Fig. 2). Altogether, these results 
imply that S1P may regulate the proliferation of CB fibroblasts.). 
 
S1P induces collagen type I production by CB fibroblasts 
Because previous studies have shown that S1P could promote epithelial-to-mesenchymal 
transition (EMT), we hypothesized that S1P could promote ʱ-smooth muscle actin (SMA) 
expression,  which  is  a  marker  of  myofibroblasts,  and  collagen  type  I  production  by  CB 
fibroblasts.  As  shown  in  Figure  3,  S1P  stimulated  the  expression  of  ʱ-SMA  in  a 
dose-dependent manner, with an approximate 3-fold increase at the highest dose tested (Fig. 
3A,  B).  Likewise,  S1P  also  promoted  type  I  collagen  production  by  CB  fibroblasts. 
Stimulation with increasing levels of S1P (0.001-1 μM) resulted in dose-dependent increases 
in collagen type I expression, with a 1.4-fold increase in type I collagen expression at the 
highest dose tested (Fig. 3C). 
 
S1P increases pro-fibrotic protein expression by CB fibroblasts 
Since TGF-β1 has the potential to mediate muscle fibrosis and PAI-1 is linked with 
decreases  in  collagen  proteolytic  degradation,  we  examined  the  effects  of  S1P  on  the 
expression of TGF-β1 and PAI-1. Using qRT-PCR, we evaluated the mRNA levels of TGF-β1 and PAI-1 induced by S1P. As shown in Figure 4A and 4B, S1P induced a dose-dependent 
increase in mRNA expression of TGF-β1 and PAI-1. Next, immunohistochemical staining 
showed  that,  compared  with  control  non-treated  CB  fibroblasts,  S1P-treated  fibroblasts 
showed  enhanced  cytoplasmic  expression  of  TGF-β1  and  PAI-1  (Fig.  4C-F).  In  parallel, 
Western blot analysis revealed that the expression of total protein for both TGF-β1 and PAI-1 
was  increased in  S1P-treated  fibroblasts.  S1P treatment  of CB  fibroblasts  resulted in  the 
induction  of  TGF-β1  (as  high  as  1.75-fold)  and  PAI-1  (as  high  as  5-fold)  (Fig.  4G-J). 
Collectively, these results suggest that S1P is capable of inducing expression of TGF-β1 and 
PAI-1 in CB fibroblasts. 
 
Discussion 
 
In the current  study, we have shown a possible role for  S1P in the  pathogenesis of 
chronic muscle fibrosis in patients with GMC. Our results indicate that the level of S1P was 
up-regulated in muscle fibrosis. Exogenous S1P stimulated CB fibroblast proliferation in a 
dose-  and  time-dependent  manner,  and  promoted  ʱ-SMA  expression  and  collagen  type  I 
production.  Furthermore,  S1P  also  induced  expression  of  TGF-β1  and  PAI-1  at  both  the 
mRNA and protein levels. These studies revealed that S1P is a multifunctional  mediator 
associated with muscle fibrogenesis. 
S1P  is  a  small,  extracellular,  sphingolipid  signaling  growth  factor  with  pleiotropic 
actions mediated by a complement of five high-affinity G protein-coupled receptors specific 
for the ligand (Takuwa et al. 2001). S1P has recently been characterized as a regulator of a variety  of  critical  cellular  events,  such  as  proliferation,  migration,  survival,  cytoskeletal 
organization, adherens junction assembly, and immune function (Ikeda et al. 2009; Katsuma 
et al. 2005). Although numerous studies have demonstrated that S1P is an important mediator 
in tissue fibrosis (Li et al. 2009), we demonstrated, for the first time, that S1P can act as a 
muscle fibrotic factor in the GMC process. 
The current study showed a strong positive staining for S1P in fibroblasts and vascular 
endothelial  cells  of  fibrotic  lesions  from  GMC  patients,  but  weak  and  sparse  staining  in 
adjacent  muscle  sections.  Previous  studies  have  shown  that  extracellular  S1P  regulates  a 
variety of cellular events via activation of five G protein-coupled receptors (Takuwa et al. 
2001), but the exact source of S1P remains unclear. Our findings directly demonstrate the S1P 
pool in fibroblasts and vascular endothelial cells, suggesting that S1P may act in a paracrine 
or  autocrine  manner  to  activate  receptors,  having  subsequent  effects  on  cell  function, 
including fibrosis. Moreover, our results revealed the up-regulated level of S1P in biopsies of 
GMC patients, and up-regulation of S1P was accompanied by an increased expression and 
deposition of collagens, as demonstrated previously (Zhao et al. 2010). Accordingly, it is 
very likely that the increased level of S1P may in turn increase the synthesis of collagens, 
leading to muscle fibrosis in GMC patients. 
In keeping with our hypothesis that S1P can up-regulate the synthesis of collagens and 
facilitate muscle fibrosis, we next examined the impacts of S1P on CB fibroblasts. We found 
that exogenous S1P stimulated CB fibroblast proliferation in  a dose- and time-dependent 
manner.  Moreover,  exogenous  S1P  could  directly  stimulate  the  expression  of  ʱ-SMA,  a 
marker of myofibroblasts, and synthesis of collagen type I, the main component of ECM. These findings suggest that, with the stimulation of S1P, CB fibroblasts were promoted to 
transform to myofibroblast-like cells, and to produce increased ECM. Similar results were 
obtained for other pro-fibrotic factors, including TGF-β, CTGF, and PDGF. Consistent with 
these findings, several previous studies have documented an increased expression of ʱ-SMA 
and accumulation of collagens in human and experimental models of fibrosis (Ikeda et al. 
2009; Li et al. 2009). 
Various  pro-fibrotic  factors,  such  as  TGF-β1,  TGF-β2,  CTGF  and  PDGF,  have  the 
potential  to  mediate  fibrogenesis  in  humans  and  experimental  animals.  Among  these 
pro-fibrotic factors, TGF-β1 has been the most frequently studied (Ask et al. 2008). TGF-β1 
has been shown to be up-regulated during tissue repair, leading to fibrosis by increasing the 
accumulation of collagen in the ECM of muscle (Razzaque et al. 2003; Waters et al. 2003). 
Here, we showed that S1P exhibited features of cross-talk with TGF-β1. In particular, S1P 
induced a dose-dependent increase at the mRNA and protein levels of TGF-β1, which is 
consistent with a related report (Hobson et al. 2001). Taken together, the direct effects of S1P 
on  fibrogenesis  and  the  indirect  effects  of  S1P  in  promoting  TGF-β1-mediated  fibrosis 
suggest that S1P has an important role in muscle fibrosis. 
Fibrotic  diseases  involve  not  only  increased  production  of  collagen,  but  also  an 
abnormal molecular process leading to collagen degradation. PAI-1 is the major physiologic 
inhibitor  of  the  plasmin  protease  system.  Plasmin  is  the  primary  effective  enzyme  in 
fibrinolysis and participates in the breakdown of ECM proteins (Lambert et al. 2001). In the 
presence  of  PAI-1,  normal  matrix  synthesis  would  be  expected  to  yield  higher  levels  of 
matrix because of the lack of plasmin activity and the attendant matrix turnover. Thus, we hypothesize that the ability of S1P to promote muscle fibrosis may involve its capacity to 
stimulate collagen production, as well as its ability to inhibit collagen degradation. Consistent 
with this hypothesis, we found that S1P up-regulated the expression of PAI-1 at the mRNA 
and protein levels. This two-way ability of S1P makes S1P an even more important mediator 
in the process of gluteal muscle scarring in patients with GMC. 
 
Conclusion 
 
The  present  study  demonstrated  that  the  expression  level  of  S1P  was  increased  in 
conjunction with excessive accumulation of collagens in specimens obtained from patients 
with  GMC.  Consistent  with  this  phenomenon, S1P  was  shown  to  stimulate  proliferation, 
ʱ-SMA expression, collagen type I production, and expression of TGF-β1 and PAI-1 by CB 
fibroblasts. S1P may regulate increased synthesis of collagens and other fibrogenic factors, 
and thereby can significantly contribute to the process of gluteal muscle scarring in patients 
with GMC. All of these findings provide important insights into the molecular mechanism 
underlying GMC and could provide specific sites for molecular therapeutic intervention to 
prevent or arrest progression of this disease. Competing interests 
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Figure 1. Immunohistochemical and HPLC analyses for S1P in contraction bands and 
unaffected adjacent muscles. Staining was carried out with antibodies against S1P (A, B), or 
without  a  primary  antibody  (control)  (C,  D)  in  contraction  bands  (A,  C)  and  unaffected 
adjacent muscles (B, D). S1P that was specifically recognized by the antibodies stained red, 
whereas  nuclei  were  counter-stained  blue.  Positive  cells  were  fibroblasts  and  vascular 
endothelial cells. Scale bars: 50 μm (A-D). (E) S1P level was measured by HPLC. The results 
showed  the  SIP  level  in  contraction  bands  compared  with  adjacent  muscles  in  23  GMC 
patients. 
 
Figure 2. S1P stimulates proliferation of CB fibroblasts of GMC patients. 5× 10
3 plated 
cells  were  synchronized  overnight  in  serum-free  media,  and  treated  with  varying 
concentrations of S1P for 24, 48 or 72 h. Note that S1P stimulated CB fibroblast proliferation 
was with time-dependent manner and upon higher concentration treatment, CB fibroblast 
proliferation was also with dose-dependent manner. Data were expressed as the fold change 
relative  to  control  (0  mM  S1P)  at  the  24  h  time  point.  Absorbance  measurements  were 
performed independently three times. 
 
Figure  3.  S1P  stimulates  α-SMA  expression  and  procollagen  type  I  C-peptide  l 
production  by  CB  fibroblasts  of  GMC  patients.  (A)  Western  blot  analysis  of  ʱ-SMA 
expression by CB fibroblasts that were serum-starved for 24 h and then treated with different 
concentrations of S1P. (B) Densitometry of protein levels of ʱ-SMA (fold-change). (C) PICP concentrations  were  determined  by  ELISA  in  supernatants  of  fibroblasts  that  were 
serum-starved for 24 h and then treated with varying concentrations of S1P. Values in each 
experiment represent the mean ±  SEM of three independent experiments. 
 
Figure  4.  S1P  stimulated  TGF-β1  and  PAI-1  expression  by  CB  fibroblasts  of  GMC 
patients. (A, B) Relative expression of TGF-β1 and PAI-1 of mRNA levels after treating with 
different concentrations of S1P (fold-change) were evaluated by qRT-PCR analysis. Increased 
cytoplasmic staining with antibodies against TGF-β1 (E) and PAI-1 (F) was noted in the 
S1P-treated  CB  fibroblasts  of  GMC  patients;  as  compared  to  the  control  group  (C,  D). 
Expression of TGF-β1, PAI-1, and β-actin in CB fibroblasts of GMC patients were examined 
by Western blot analysis (G, H). Data were normalized to β-actin expression and presented as 
a fold-change (I, J).  
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